AdipoRon and Pancreatic Ductal Adenocarcinoma:a future perspective in overcoming chemotherapyinduced resistance?
作者机构：Department of Precision MedicineUniversity of Campania“Luigi Vanvitelli”Naples 80138Italy
出 版 物：《Cancer Drug Resistance》 (癌症耐药（英文）)
年 卷 期：2022年第5卷第3期
页 面：625-636页
学科分类：1002[医学-临床医学] 100214[医学-肿瘤学] 10[医学]
主 题：PDAC AdipoRon gemcitabine resistance
摘 要：The latest scientific knowledge has provided additional insights accountable for the worst prognosis for pancreatic ductal adenocarcinoma(PDAC).Among the causative factors,the aptitude to develop resistance towards approved medications denotes the master key for understanding the lack of improvement in PDAC survival over the *** though several compounds have achieved encouraging results at preclinical stage,no new adjuvant agents have reached the bedside of PDAC patients *** adiponectin receptor agonist AdipoRon is emerging as a promising anticancer drug in different cancer models,particularly in *** on the existing findings,we recently reinforced its candidacy in PDAC cells,proposing AdipoRon either as a suitable partner in gemcitabinebased treatment or as an effective drug in resistant *** the current state-of-the-art,herein we provide a critical perspective on AdipoRon to figure out whether this receptor agonist can potentially be considered a future therapeutic choice in overcoming chemotherapy-induced resistance,expressly in PDAC.
维普期刊数据库